Dummer R, Flaherty KT, Robert C, Arance A, et al. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. J Clin Oncol 2022 Jul 21:JCO2102659. doi: 10.1200/JCO.21.02659.
PMID: 35862871